Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6607 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-10-28 (pharmaphorum.com)
Biogen shows its IgAN hand with felzartamab data
The main asset in Biogen's $1.8bn takeover of HI-Bio, anti-CD38 drug felzartamab, delivers a positive phase 2 readout in rare disease IgAN.
Read more
2024-10-24 (saudeonline.pt)
Biogen presents data on spinal muscular atrophy
The DEVOTE findings support the clinical benefits of a high-dose regimen (50/28 mg) of spinal muscular atrophy treatment.
Read more
2024-09-26 (aktiencheck.de)
Biogen Stock: Positive Lupus Data Brings a Surprise! (Barclays)
Biogen Stock: Positive Lupus Data Brings a Surprise! (Barclays) | aktiencheck.de
Read more
2024-09-25 (tradingsat.com)
Biogen idec: Well oriented after data in lupus
(CercleFinance.com) - UCB climbs 3% in Brussels after the announcement, with its partner Biogen, of the first positive results of the phase 3 study...
Read more
2024-09-25 (tradingsat.com)
Biogen idec: Positive phase III data in lupus
(CercleFinance.com) - UCB and Biogen announce initial positive results from the PHOENYCS GO phase 3 study evaluating their dapirolizumab pegol, in…
Read more
2024-09-18 (hitnews.co.kr)
Alzheimer's treatment Lechembe: A case of long-term medication
The FDA officially approved Leqembi (Lecanemab), an Alzheimer's disease treatment jointly developed by Biogen and Esai, on July 6, 2023. Rechemvi is a humanized monoclonal antibody drug targeting beta-amyloid (Aβ) and is an improved form of Adduhelm, which was first approved by two companies for the same target. Now that lecanemab has been in clinical use in the U.S. for just over a year, doctors are asking how long they should continue to be treated with the antibody. But the answer is unknown. Eisai has filed a ‘supplemental biological authorization application’ with the FDA.
Read more
2024-07-22 (ciolook.com)
Nishtha Jain: Bridging Technology and Healthcare for Better Patient Care
Innovating Healthcare Solutions!
Read more
2024-06-08 (deraktionaer.de)
Biogen stock
Current prices, master data, charts and further information on the Biogen security (ISIN: US09062X1037, WKN: 789617)
Read more
2024-02-05 (biospace.com)
5 Alzheimer’s Data Readouts to Watch in 2024 | BioSpace
With one disease-modifying therapy already reaching patients and another expected to soon, several biopharma companies anticipate key data for novel assets in the coming 12 months.
Read more
2023-10-19 (informazione.it)
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer 's diseaseAdditional late-breaking presentations from the CLARITY AD study explore predictive biomarkers and novel subcutaneous administration of LEQEMBI®( lecanemab-irmb) CAMBRIDGE,
Read more
2023-10-19 (financialpost.com)
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer’s disease Additional late-breaking...
Read more
2022-03-17 (pharmaphorum.com)
Biogen finally publishes its phase 3 Aduhelm data
After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to look at the data and judge its efficacy and safety.
Read more